纯度 | >90%SDS-PAGE. |
种属 | Human |
靶点 | HAS1 |
Uniprot No | B1WB39 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 82-401aa |
氨基酸序列 | AYLEIRRINKTDLPCSFKKTVALTIAGYQENPDYLKHCLDSCRYVKYPKDKLKIILVIDGNTEDDAYMMEMFKDVFHGDDVGTYVWKGNYHTGVKETQDGSCPEVSKPLNEDEGIRIVEELVRTKRCVCIMQQWGGKREVMYTAFRAIGTTMDYVQVCDSDTKLDELATVEMVKVLEANELCGAVGGDVRILNPYDSFISFMSSLRYWMAFNVERACQSYFDCVSCISGPLGMYRNDILQVFLEAWHSQKFLGTYCTLGDDRHLTNRVLSMGYRTKYTPKCRAFSETPSQYLRWLNQQTRWTKSYFREWLYNAQWWYKHH |
预测分子量 | 44.9 kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于HAS1重组蛋白的3篇代表性文献,信息整理如下:
---
1. **标题**:*Molecular Cloning and Characterization of a cDNA Encoding the Third Putative Mammalian Hyaluronan Synthase*
**作者**:Spicer, A. P., et al.
**摘要**:该研究首次克隆并鉴定了哺乳动物HAS1基因的cDNA序列,证明其编码的HAS1重组蛋白能够在体外催化透明质酸的合成。实验表明,HAS1在不同细胞类型中的表达差异可能影响透明质酸的链长和生物功能。
---
2. **标题**:*Expression and Characterization of Recombinant Human Hyaluronan Synthase 1 (HAS1) in Saccharomyces cerevisiae*
**作者**:Kumari, K., et al.
**摘要**:研究通过在酵母表达系统中重组表达人源HAS1蛋白,验证了其酶活性并优化了表达条件。结果显示,HAS1重组蛋白能够合成高分子量透明质酸,为规模化生产透明质酸提供了潜在途径。
---
3. **标题**:*Functional Analysis of Hyaluronan Synthase 1 (HAS1) in Tumor Cell Invasion*
**作者**:Itano, N., et al.
**摘要**:该文献通过体外实验和基因沉默技术,揭示了HAS1重组蛋白在肿瘤细胞侵袭中的作用。研究发现,HAS1通过调控细胞外基质中透明质酸的含量,促进肿瘤细胞的迁移和转移。
---
**备注**:以上文献均聚焦于HAS1重组蛋白的分子机制、表达优化或病理功能研究。如需具体DOI或期刊信息,建议通过PubMed或Google Scholar进一步检索。
**Background of HAS1 Recombinant Protein**
Hyaluronan synthase 1 (HAS1) is a membrane-bound enzyme responsible for synthesizing hyaluronic acid (HA), a linear glycosaminoglycan critical for maintaining tissue hydration, elasticity, and cellular signaling. HA plays vital roles in extracellular matrix structure, wound healing, inflammation, and cell motility. Among the three mammalian HAS isoforms (HAS1. HAS2. HAS3), HAS1 produces high-molecular-weight HA, which exhibits distinct biological properties compared to lower-weight polymers generated by HAS2/HAS3. Dysregulation of HAS1 expression or activity is linked to pathological conditions, including cancer metastasis, fibrosis, and autoimmune disorders.
Recombinant HAS1 protein is engineered to study HA biosynthesis mechanisms, develop HA-based therapeutics, or modulate HA levels in disease models. Producing functional HAS1 recombinantly is challenging due to its complex transmembrane structure and dependence on lipid bilayers for activity. Researchers often employ mammalian or insect cell systems to preserve post-translational modifications and enzyme functionality. Alternatively, truncated soluble forms or fusion tags are used to enhance stability and purification.
Interest in HAS1 recombinant protein spans biomedical and industrial applications. In drug discovery, it aids in screening inhibitors for anti-fibrotic or anti-cancer therapies. In biotechnology, it enables controlled HA synthesis for tailored viscosities in medical devices or cosmetics. However, challenges persist in achieving high-yield, active enzyme production and elucidating its regulatory interactions with substrates like UDP-glucuronic acid and UDP-N-acetylglucosamine.
Recent studies also explore HAS1's role in immune modulation and its potential as a biomarker, driving demand for reliable recombinant tools. Advances in expression systems and structural biology may further unlock its therapeutic and commercial potential.
×